Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Glenmark Pharmaceuticals Limited

NSE: GLENMARKPharmaceuticals

Share price

₹2,192.20

-3.95% close of 8 Oct 2026

Market cap ₹61,382 CrP/E 19.7

Business score

How strong the business is, in one number. The parts behind it are in Pro.

75

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹61,382 Cr

P/E ratio

19.7

P/B ratio

5.9

ROCE

39.8%

ROE

23.6%

Dividend yield

0.2%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹2,515.0052-week low ₹1,810.40

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 32.9% over the past year, and 14.6% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 17.9% to 25.4% over the last four years.

Whether it grew faster than its sector

It grew 14.6% a year against a sector median of 13.1% — 1.5 percentage points faster.

Room to re-rate, or risk of de-rating

At 19.7× earnings against a market that pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 20.8×, the 46th percentile of its own range.

Whether growth justifies the valuation

Priced at 0.3 times its growth rate, on earnings growth of 61%.

Profit growthPrice per ₹1 profitPer 1% growth
Glenmark Pharmaceuticals Limited — this one61%/yr19.7×₹0.32
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 7 of 130 on returns, 45 of 127 on growth, 35 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 39.8% on capital, ahead of 95% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

No — Over the last five years it made ₹4086 crore of cash from the business but spent ₹4339 crore on plant and equipment, ₹253 crore more than it made, paid from its own cash and investments. And the profit is real: of every 100 rupees it reported over 12 years, about 140 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back more slowly than it used to: it went from being waiting 65 days for its cash to waiting 81 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 9 checks clear · 89%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue grew 23% and profit reached Rs 483 Cr against a very weak year-ago quarter

Announced 31 Jul 2026 · Consolidated

Revenue

₹4,018 Cr

Revenue vs last year

+23.1%

Revenue vs last quarter

+6.6%

Net profit

₹483 Cr

Profit vs last year

+927.3%

Profit vs last quarter

+60.4%

Net margin

12.0%

EPS

₹17.11

Earnings call transcript · 3 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹61,382 Cr
Prev close
₹2,192.20
52w High
₹2,538
52w Low
₹1,793
Enterprise value
₹61,295 Cr
Beta
0.8
Price CAGR 1y
18.0%
Price CAGR 3y
43.0%
Price CAGR 5y
34.0%
Price CAGR 10y
9.0%

Ratios

Return on assets
6.8%
PEG ratio
0.3
P/E ratio
19.7
P/B ratio
5.9
EV / EBITDA
13.7
Industry P/E
38.0
ROCE
39.8%
ROCE 5y average
19.4%
ROE
23.6%
Debt / Equity
0.1
Interest coverage
10.5
Dividend yield
0.2%
ROE 3y average
-3.0%
ROE last year
24.0%

Annual P&L

Annual revenue
₹16,983 Cr
Annual profit
₹1,362 Cr
Operating margin
27.0%
Net profit margin
8.0%
EBITDA margin
26.9%
Sales growth 3y
13.6%
Sales growth 5y
9.2%
Profit growth 3y
61.0%
Profit growth 5y
19.0%
EPS
₹48.3
Sales growth TTM
33.0%
Profit growth TTM
134.0%
Dividend payout
10.0%

Quarter P&L

Sales latest quarter
₹4,018 Cr
Profit latest quarter
₹483 Cr
YoY quarterly sales growth
23.1%
YoY quarterly profit growth
927.7%
OPM latest quarter
20.0%

Balance Sheet

Book Value
₹375
Face Value
₹1.0
Total debt
₹594 Cr
Total cash
₹1,176 Cr
Borrowings
₹594 Cr
Reserves / Equity
374.4

Cash Flow

Operating cash flow
₹3,445 Cr
Free cash flow
₹2,090 Cr
FCF yield
3.1%
Net cash flow
-₹501 Cr

Shareholding

Promoter holding
46.6%
FII holding
20.9%
DII holding
18.6%
Public holding
13.8%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.84,27,3220.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.42,54,5310.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.41,79,3890.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,15,0120.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.41,10,9150.10362.1125.52,026.329.117.8
Cipla1,327.2030.01,07,2210.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.41,03,2610.04574.129.64,030.612.913.5
Glenmark Pharma.2,282.3020.664,4120.22482.885.54,018.523.139.8
Median417.9034.52,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales3,0363,2072,5073,0633,2443,4343,3883,2563,2646,0473,9013,7714,018
Expenses2,5992,7452,7152,5592,6562,8322,7872,6952,6843,6873,0313,0083,214
Material Cost795732723775731601
Change in Inventories-51-298-78-229-5.21-16
Purchases of Stock-in-Trade345581620749446661
Employee Cost7377631,086841887935
Other Expenses8709061,3378949481,033
Operating Profit437462-2095045886026005615812,360870763805
OPM %1414-8.3216181818171839222020
Other Income-32-20587351313931-361-297-1,184-140-18466
Exceptional items (within Other Income)-373-323-1,385-184-3730
Interest112121134149404852675866414354
Depreciation142141147151118120123125130141154148173
Profit before tax151-6-403555462473456896967534388643
Tax %-14997-18319262524455137242225
Net Profit173-62-331-1,214340354348447610403301483
EPS in Rs5.31-2.90-12-431213120.161.6622141117
Diluted EPS in Rs0.161.6622141117

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales6,5637,5629,0799,0749,86510,64110,94412,30511,58311,81313,32216,98317,737
Expenses5,3486,1257,0437,4578,2808,9428,8609,9789,94810,61810,97012,41012,940
Material Cost3,0012,961
Change in Inventories-214-611
Purchases of Stock-in-Trade1,5662,397
Employee Cost3,0223,578
Other Expenses3,5954,085
Operating Profit1,2141,4372,0371,6171,5861,6992,0842,3271,6351,1952,3514,5724,797
OPM %18192218161619191410182727
Other Income-18020-448937519195-101-10336-259-1,805-1,443
Exceptional items (within Other Income)-373-2,266
Interest190179237286335377353298349516207209204
Depreciation300234264302326417444487569582486573617
Profit before tax5441,0441,4911,1191,3011,0961,3821,4417074341,3991,9852,533
Tax %6129262829293031474302531
Net Profit2097431,109804925776970994377-1,4341,0471,3621,798
EPS in Rs7.722639283328343311-53374864
Diluted EPS in Rs3748
Dividend Payout %26857697724-5710

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
8%
5 years
9%
3 years
14%
TTM
33%

Compounded profit growth

10 years
12%
5 years
19%
3 years
61%
TTM
134%

Stock price CAGR

10 years
9%
5 years
34%
3 years
43%
1 year
18%

Return on equity

10 years
7%
5 years
2%
3 years
-3%
Last year
24%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital272828282828282828282828
Reserves1,7563,6014,4645,1355,5776,0427,0369,0589,4467,8208,82110,484
Borrowings3,8003,9884,7244,6394,4494,8694,9863,9624,6081,2312,473594
Other Liabilities2,7262,5752,5482,7933,2353,7293,5244,0035,2895,2794,6698,801
Minority Interest-0.37-0.32
Total Liabilities8,30910,19311,76412,59513,28914,66815,57517,05219,37114,35815,99119,907
Fixed Assets2,0152,5942,7553,0303,6705,0295,1295,8875,4224,2104,4875,915
CWIP4775437081,1221,3991,2221,3821,0101,190662835909
Investments1717161530252550457905642
Other Assets5,7997,0398,2858,4298,1908,3939,04010,10512,7158,69710,61313,041
Total Assets8,30910,19311,76412,59513,28914,66815,57517,05219,37114,35916,05019,908

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity4823456571,6481,3241,3921,1311,109625-265-8283,445
Cash from Investing Activity-712-950-1,001-1,003-883-774-662-316-5154,38758-1,237
Cash from Financing Activity199699543-468-739-445-442-520-77-3,906787-2,709
Net Cash Flow-3193199177-297174282723221517-501
Free Cash Flow-56-544-7662571261645632075-1,162-1,5752,090

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1401209794818386921155792107
Inventory Days247249299244244211230208203208254264
Days Payable379308243225241210226190172210256288
Cash Conversion Cycle861152113858490110147569083
Working Capital Days47511259964546765141-24481
ROCE %161921151514151610121940

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters474747474747474747474747
FIIs252421212324232121192021
DIIs101113141314151819201919
Government0.040.040.040.040.040.040.040.040.040.040.040.04
Public181919181716161514141414
No. of Shareholders2,32,6852,09,9311,99,4511,92,6301,93,9491,95,0591,92,7241,90,2101,98,7892,01,5841,96,1052,11,418

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +13.3% (₹1,935.60 → ₹2,192.20)Brick size ₹68.35 (fixed)Bricks 20
₹2,000₹2,400₹2,192Dec '25Apr '26Aug '26
Price moved up one brickPrice moved down one brickLast close ₹2,192.20 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

58,90,633inr

2026-03-31

News

News and filings about Glenmark Pharmaceuticals Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Active Pharmaceutical Ingredient (API)
  • Key Starting Materials (KSMs)

Buys drug ingredients from

Sells to

  • AbbVie Inc · Out-licensed ISB 2001 trispecific antibody (oncology) via subsidiary Ichnos Glenmark Innov…

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE935A01035

Plants

  • Glenmark Baddi
  • Glenmark CSN (Aurangabad)
  • Glenmark Goa
  • Glenmark Indore (Pithampur)
  • Glenmark Monroe
  • Glenmark Nalagarh
  • Glenmark Nashik
  • Glenmark Pilar
  • Glenmark Sikkim
  • Glenmark Vysoke Myto

News impact

Big market events that reach Glenmark Pharmaceuticals Limited, and how the effect spreads.

23 Sept, 10:54 IST · Market event · high impact

US FDA clears Glenmark's Goa unit with VAI status

The US FDA cleared Glenmark's Goa drug factory with a mostly-clean VAI report, protecting its American sales and shares, while rival drugmakers and suppliers see no real change.

Healthcare

Who it hits first

  • Glenmark Pharmaceuticals, a Mumbai drugmaker selling in the US, got a VAI result (a mostly-clean report card asking for voluntary fixes) from the US FDA for its Goa factory, inspected June 22-30.
  • The clearance removes the fear of an import ban, so medicines made in Goa can keep shipping to America.
  • Rival drugmakers and Glenmark's raw-material suppliers see no direct change from this single-factory result.

Who may gain

  • Glenmark: its Goa plant keeps exporting to the US without an import alert.
  • US buyers and patients: steady supply of Glenmark medicines from Goa.
  • Glenmark shareholders: a regulatory overhang lifts, supporting the share price.

Along the supply chain

Downstream

Downstream, US distributors and pharmacies continue receiving Goa-made drugs without disruption; the pack lists no customer of Glenmark to name further.

Upstream

Upstream, Glenmark's listed suppliers (Alivus, Concord Bio, Sakar and others) keep their existing Goa-linked orders, but a clearance creates no new ingredient demand.

Where demand moves

Business

Real business is protected, not added: Goa-made medicines keep flowing to US distributors and pharmacies, preserving existing export revenue; no rival gains or loses orders from this.

Capital

Capital relief trade: Glenmark shares should firm as the import-alert risk fades, while peer pharma stocks see only faint sympathy flows.

How it spreads across sectors

Healthcare

Mild relief tone: one fewer FDA overhang steadies sentiment for US-exposed drugmakers, but sales move nowhere.

When it plays out

Immediate

Glenmark shares firm as the VAI outcome circulates and import-alert fears unwind.

Medium term

Sustained US shipments and new approvals from the Goa site convert relief into revenue.

Short term

Management commentary on the observations and any remediation timeline sets the next move.

Who it hits first

  • US-facing Indian generic exporters (DRREDDY, AUROPHARMA, LUPIN, ZYDUSLIFE, GLAND) face a long-dated tariff threat with zero near-term cost
  • Sentiment hit today; Nifty Pharma -1.3%

Who may gain

  • Domestic-focused pharma/hospitals (APOLLOHOSP, MANKIND, ABBOTINDIA) relatively insulated
  • US-based generic manufacturers long-term if reshoring occurs

Along the supply chain

Downstream

US pharmacies/PBMs and patients would bear higher generic costs if the tariff ever takes effect, which is the political friction that makes near-term enactment on essential generics unlikely.

Upstream

Indian API/intermediate suppliers to these formulators see no near-term change; a post-2028 US reshoring push could shift some API demand but also open US-site sourcing.

Where demand moves

Business

No near-term demand change (0% tariff for 2 years). If enacted post-2028, US buyers of Indian generics would face higher landed cost, incentivising reshoring or supplier switching; specialty/injectable makers are harder to displace.

Capital

Near-term risk-off rotation within pharma from high-US-generics names toward domestic-facing pharma and hospitals; the muted, recoverable Sept-2025 precedent limits sustained outflows.

How it spreads across sectors

Healthcare

Domestic hospitals/branded pharma relatively insulated, mild defensive bid

Pharma

US-generic exporters sentiment-negative near-term, neutral medium-term given phasing

When it plays out

Immediate

Sentiment-driven dip in US-exposed generic exporters (Nifty Pharma -1.3%); no earnings impact

Medium term

Neutral through 2026-27 (0% tariff); structural risk only from Aug-2028 (100%) / Aug-2029 (200%) if unmodified — 2 years to reshore or requalify supply

Short term

Wait-and-watch; watch for exemptions/clarifications on essential generics and any reshoring announcements

Who it hits first

  • Pentagon Biosecure blacklist on WuXi AppTec — US biotech contracts pivot to India CRAMS; multi-year tailwind

Who may gain

  • SYNGENE
  • DIVISLAB
  • LAURUSLABS
  • GLENMARK

Along the supply chain

Downstream

US biotech delivery timelines stabilize; cost slightly higher than China but compliance certain

Upstream

Higher API + intermediate procurement from India over China

Where demand moves

Business

US biotech R&D contracts reroute from WuXi to Indian CDMOs; Asian capacity rationalisation

Capital

Long-only allocation into Indian CRAMS theme; ETF flows benefit

How it spreads across sectors

CRAMS

primary beneficiary

Healthcare

CRAMS sub-sector elevation

Pharma

structural positive

When it plays out

Immediate

Sector pop 2-4%

Medium term

Multi-year capacity expansion + multiple expansion

Short term

Contract pipeline visibility improves

Who it hits first

  • Cipla +2-4% on incremental US revenue + pipeline re-rate

Who may gain

  • Cipla direct; SunPharma/ZydusLife as sector rotation names

Along the supply chain

Downstream

US pharmacies/distributors gain supply alternative

Upstream

API suppliers to Cipla (some China, some domestic) see incremental demand

Where demand moves

Business

US respiratory generic prescription shift — Cipla gains share from brand originator

Capital

Pharma sector rotation driven by HSBC India downgrade; flight to defensives

How it spreads across sectors

Healthcare

Positive — rotation destination

Pharma

Positive — approval boosts sector sentiment

When it plays out

Immediate

Cipla +2-4% on approval news

Medium term

Full-year revenue contribution by Q2FY28

Short term

Launch execution + market share capture over 2 quarters

Who it hits first

  • API-heavy pharma cos face input cost increase + compliance capex

Who may gain

  • Formulation-heavy pharma (Cipla, Sun) relatively insulated

Along the supply chain

Downstream

API consumers (formulation firms, chemicals) face cost pass-through

Upstream

Ammonia suppliers get tighter supervision

Where demand moves

Business

API cost up → formulation margin pressure for domestic captive; export opportunity for alt suppliers

Capital

Money rotates from API-heavy to formulation-heavy pharma

How it spreads across sectors

Pharmaceuticals

API -2 to -4%, Formulation ±1%

When it plays out

Immediate

Laurus Labs, Divi's -2 to -4%; Sun/Cipla flat

Medium term

Compliance cost absorbed; structural winners emerge

Short term

Rule implementation timeline drives re-rating

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

31 Aug 2026unspecified₹2.5
3 Oct 2025interim₹2.5
15 Sep 2025unspecified₹2.5
13 Sep 2024unspecified₹2.5
18 Sep 2023unspecified₹2.5
12 Sep 2022unspecified₹2.5
8 Sep 2021unspecified₹2.5
17 Sep 2020unspecified₹2.5

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.